Capital Investment Services of America Inc. Acquires 683 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Capital Investment Services of America Inc. lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 41,416 shares of the company’s stock after purchasing an additional 683 shares during the period. IDEXX Laboratories comprises approximately 2.3% of Capital Investment Services of America Inc.’s holdings, making the stock its 22nd biggest position. Capital Investment Services of America Inc.’s holdings in IDEXX Laboratories were worth $20,800,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. Moneta Group Investment Advisors LLC increased its holdings in IDEXX Laboratories by 121,647.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after acquiring an additional 7,441,162 shares in the last quarter. Norges Bank purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $336,416,000. Alliancebernstein L.P. increased its holdings in IDEXX Laboratories by 11.5% in the 4th quarter. Alliancebernstein L.P. now owns 3,240,710 shares of the company’s stock worth $1,322,080,000 after acquiring an additional 334,020 shares in the last quarter. Morgan Stanley increased its holdings in IDEXX Laboratories by 36.0% in the 4th quarter. Morgan Stanley now owns 986,232 shares of the company’s stock worth $402,344,000 after acquiring an additional 260,926 shares in the last quarter. Finally, Winslow Capital Management LLC increased its holdings in IDEXX Laboratories by 31.4% in the 4th quarter. Winslow Capital Management LLC now owns 873,084 shares of the company’s stock worth $356,183,000 after acquiring an additional 208,387 shares in the last quarter. 86.85% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP James F. Polewaczyk sold 22,909 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $510.56, for a total value of $11,696,419.04. Following the completion of the sale, the executive vice president now directly owns 10,038 shares in the company, valued at $5,125,001.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP James F. Polewaczyk sold 22,909 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $510.56, for a total value of $11,696,419.04. Following the completion of the sale, the executive vice president now directly owns 10,038 shares in the company, valued at $5,125,001.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 13,424 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $512.01, for a total value of $6,873,222.24. Following the completion of the sale, the chief executive officer now owns 72,925 shares of the company’s stock, valued at $37,338,329.25. The disclosure for this sale can be found here. Insiders sold a total of 52,360 shares of company stock worth $26,743,411 over the last three months. 2.11% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on IDXX shares. Atlantic Securities lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $610.00 target price for the company. in a report on Wednesday, August 2nd. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $525.00 to $500.00 and set a “hold” rating for the company in a report on Friday. StockNews.com initiated coverage on shares of IDEXX Laboratories in a report on Thursday, August 17th. They set a “buy” rating for the company. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $590.00 to $600.00 and gave the company an “overweight” rating in a report on Thursday, August 3rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $550.00 to $600.00 and gave the company an “overweight” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $571.67.

IDEXX Laboratories Price Performance

Shares of IDXX stock traded down $11.39 on Friday, reaching $450.69. The company’s stock had a trading volume of 770,079 shares, compared to its average volume of 452,822. The stock’s fifty day simple moving average is $510.75 and its 200-day simple moving average is $490.61. IDEXX Laboratories, Inc. has a 1 year low of $317.06 and a 1 year high of $564.73. The company has a current ratio of 1.33, a quick ratio of 0.89 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $37.41 billion, a price-to-earnings ratio of 47.84, a price-to-earnings-growth ratio of 2.66 and a beta of 1.20.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 1st. The company reported $2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.24. IDEXX Laboratories had a net margin of 22.52% and a return on equity of 104.84%. The firm had revenue of $943.63 million during the quarter, compared to analyst estimates of $927.84 million. Analysts forecast that IDEXX Laboratories, Inc. will post 9.82 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.